Pharmacologic strategies to target oxidative stress in heart failure

Current Heart Failure Reports

Volumn 9, Issue 1, 2012, Pages 14-22

  Ahmed, Zain ^a   Wilson Tang, W H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antioxidants; Coenzyme Q10; Heart failure; Omega 3 fatty acids; Oxidative stress; Pharmacologic therapy; Reactive oxygen species; Vitamin supplementation; Xanthine oxidase; Xanthine oxidase inhibitors

Indexed keywords

ALLOPURINOL; ALPHA TOCOPHEROL; ASCORBIC ACID; DIMETHYLTHIOUREA; NITRIC OXIDE; OMEGA 3 FATTY ACID; OXIPURINOL; PLACEBO; PROBUCOL; PROPIONYLCARNITINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESVERATROL; UBIQUINOL CYTOCHROME C REDUCTASE; UBIQUINONE; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG MECHANISM; ELECTRON TRANSPORT; ENZYME ACTIVITY; HEART FAILURE; HUMAN; MITOCHONDRION; OXIDATIVE STRESS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTIOXIDANTS; HEART FAILURE; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84862840761     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-011-0081-5     Document Type: Review

References (83)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics\-2011 update. Circulation. 2011;123:209-18.
2. Finkel T. Signal transduction by reactive oxygen species in non-phagocytic cells. J Leukoc Biol. 1999;65:337-40. (Pubitemid 29109705)
3. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956;11:298-300.
4. Sugamura K, Keaney JJF. Reactive oxygen species in cardiovascular disease. Free Radical Biology and Medicine. 2011;51:978-992.
5. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer. 1996;32A:30-8.
6. Whaley-Connell A, McCullough PA, Sowers JR. The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med. 2011;12:21-9.
7. Facecchia K, Fochesato LA, Ray SD, et al. Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies. Journal of Toxicology 2011.
8. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005;115(3):500-8. (Pubitemid 40322219)
9. Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. CurrMedRes Opin. 2004;20:1559-69. (Pubitemid 39457544)
10. Ono H, Minatoguchi S, Watanabe K, et al. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res. 2008;31:271-9. (Pubitemid 351461107)
11. Ishimitsu T, Numabe A, Masuda T, et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertension Research: Official Journal of the Japanese Society of Hypertension. 2009;32:962-8.
12. Li J, Sun YM, Wang LF, et al. Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. Clin Cardiol. 2010;33:222-7.
13. Shah AM, Seddon M, Looi YH. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart. 2007;93:903-7. (Pubitemid 47122034)
14. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med. 2002;33:774-97. (Pubitemid 35232313)
15. Jarasch E-D, Grund C, Bruder G, et al. Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell. 1981;25:67-82. (Pubitemid 11087436)
16. Dejong J, Schoemaker R, Dejonge R, et al. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol. 2000;32:2083-9.
17. Spiekermann S, Landmesser U, Dikalov S, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxi-dase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2003;107:1383-9. (Pubitemid 36350736)
18. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure. Circulation. 2003;107:1991-7.
19. Hare JM. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation. 2003;107:1951-3. (Pubitemid 36506064)
20. Ekelund UE, Harrison RW, Shokek O, et al. Intravenous allopuri-nol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circulation. 1999;85:437-45. (Pubitemid 29409620)
21. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail. 2009;11:444-52.
22. Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Biophys. 2002;397:342-4. (Pubitemid 34852301)
23. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245-313. (Pubitemid 46209993)
24. Song E, Jaishankar G, Saleh H, et al. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy. 2011;9:10-0.
25. Lambeth JD. Nox enzymes and the biology of reactive oxygen. Nat Rev Immunol. 2004;4:181-9. (Pubitemid 38339084)
26. Wingler K, Wunsch S, Kreutz R, et al. Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med. 2001;31:1456-64. (Pubitemid 33145316)
27. Lassegue B, Sorescu D, Szocs K, et al. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circulation. 2001;88:888-94. (Pubitemid 32441466)
28. Johar S, Cave AC, Narayanapanicker A, et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB. 2006;20:1546-8.
29. Mollnau H, Wendt M, Szocs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circulation. 2002;90:E58-65.
30. Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myo-cardial infarction. Ann Intern Med. 2004;141:693-704. (Pubitemid 39434842)
31. Bell RM, Cave AC, Johar S, et al. Pivotal role of NOX-2-containing NADPH oxidase in early ischemic preconditioning. FASEB. 2005;19:2037-9. (Pubitemid 41759757)
32. Looi YH, Grieve DJ, Siva A, et al. Involvement of NOX2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension. 2008;51:319-25. (Pubitemid 351159945)
33. Vignais PV. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. CMLS. 2002;59:1428-59. (Pubitemid 35239301)
34. Satoh M, Ogita H, Takeshita K, et al. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A. 2006;103:7432-7. (Pubitemid 43727850)
35. Liao JK, Takemoto M, Node K, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-37. (Pubitemid 33091980)
36. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circulation. 2006;98:730-42.
37. Sadoshima J, Kuroda J, Ago T, et al. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:15565-15570.
38. Zhang M, Brewer AC, Schroder K, et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:18121-18126.
39. Naik E, Dixit VM. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med. 2011;208:417-20.
40. Li Y, Huang T-T, Carlson EJ, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet. 1995;11:376-81.
41. Nojiri H, Shimizu T, Funakoshi M, et al. Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem. 2006;281:33789-801. (Pubitemid 46036756)
42. Reinartz M, Ding Z, Flogel U, et al. Nitrosative stress leads to protein glutathiolation, increased s-nitrosation, and up-regulation of peroxiredoxins in the heart. J Biol Chem. 2008;283:17440-9.
43. Ungvari Z, Gupte SA, Recchia FA, et al. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol. 2005;3:221-9. (Pubitemid 40933045)
44. Pacher P, Schulz R, Liaudet L, et al. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci. 2005;26:302-10. (Pubitemid 40733523)
45. Elahi MM, Naseem KM, Matata BM. Nitric oxide in blood. The nitrosative-oxidative disequilibrium hypothesis on the pathogene-sis of cardiovascular disease. FEBS J. 2007;274:906-23. (Pubitemid 46204411)
46. Casadei B, Lim G, Venetucci L, Eisner DA. Does nitric oxide modulate cardiac ryanodine receptor function? Implications for excitation-contraction coupling. Cardiovasc Res. 2008;77:256-64. (Pubitemid 351197636)
47. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296:2391-4. (Pubitemid 34734213)
48. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000;275:37524-32. (Pubitemid 32004861)
49. Gladwin MT, Shiva S, Wang X, et al. Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeo-stasis. Nat Chem Biol. 2006;2:486-93. (Pubitemid 44266311)
50. Tang WH, Katz R, Brennan ML, et al. Usefulness of myeloperox-idase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol. 2009;103:1269-74.
51. Mingorance C, Rodriguez-Rodriguez R, Justo ML, et al. Pharmacological effects and clinical applications of propionyl-L-carnitine. Nutr Rev. 2011;69:279-90.
52. Resveratrol in cardiovascular disease. Heart Failure Review. 2011.
53. Nakamura R, Egashira K, Machida Y, et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation. 2002;106:362-7. (Pubitemid 34778962)
54. Kinugawa S, Tsutsui H, Hayashidani S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circulation. 2000;87:392-8.
55. Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 1998;97:363-8. (Pubitemid 28074337)
56. Enstrom JE, Kanim LE, Klein MA. Vitamin-C Intake and Mortality among a Sample of the United-States Population. Epidemiology. 1992;3:194-202.
57. Osganian SK, Stampfer MJ, Rimm E, et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol. 2003;42:246-52. (Pubitemid 36851413)
58. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2008;300:2123-33.
59. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342:154-60. (Pubitemid 30051646)
60. Marchioli R, Levantesi G, Macchia A, et al. Vitamin E increases the risk of developing heart failure after myocardial infarction: Results from the GISSI-Prevenzione trial. J Cardiovasc Med. 2006;7:347-50. (Pubitemid 44145638)
61. Thomson MJ, Frenneaux MP, Kaski JC. Antioxidant treatment for heart failure: friend or foe? QJM. 2009;102:305-10.
62. Brown BG, Crowley J. Is there any hope for vitamin E? JAMA. 2005;293:1387-90. (Pubitemid 40381493)
63. Engberding N, Spiekermann S, Schaefer A, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation. 2004;110:2175-9. (Pubitemid 39372497)
64. Ellestad MH. Xanthine oxidase inhibitors the unappreciated treatment for heart failure. Cardiovasc Hematol Disord Drug Targets. 2007;7:291-4.
65. Hayashi K, Kimata H, Obata K, et al. Xanthine oxidase inhibition improves left ventricular dysfunction in dilated cardiomyopathic hamsters. J Card Fail. 2008;14:238-44. (Pubitemid 351434590)
66. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. Journal of the American College of Cardiology 2008;51:2301-2309. (Pubitemid 351783365)
67. Nasr G, Maurice C. Allopurinol and global left myocardial function in heart failure patients. J Cardiovasc Dis Res. 2010;1:191-5.
68. Calder PC. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie. 2009;91:791-5.
69. Witte KK, Clark AL. Marine polyunsaturated fatty acids in heart failure. Are the theoretical benefits matched by the clinical data? Polskie Archiwum Medycyny Wewnetrznej. 2009;119:162-9.
70. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyun-saturated fatty acids and cardiovascular diseases. J Am Coll Car-diol. 2009;54:585-94.
71. Tang WH, Samara MA. Polyunsaturated fatty acids in heart failure: should we give more and give earlier? J Am Coll Cardiol. 2011;57:880-3.
72. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyun-saturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223-30.
73. Nodari S, Triggiani M, Campia U, et al. Effects of n-3 polyunsat-urated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57:870-9.
74. Moertl D, Hammer A, Steiner S, et al. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J. 2011;16:915.e1-9.
75. Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol. 2009;104:1708-16.
76. Dai D-F, Chen T, Szeto H, et al. Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy. J Am Coll Car-diol. 2011;58:73-82.
77. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and mi-tochondrial DNA damage in heart failure. Circ J. 2008;72:31-7.
78. Shiomi T, Tsutsui H, Matsusaka H, et al. Overexpression of gluta-thione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation. 2004;109:544-9. (Pubitemid 38168520)
79. Dai DF, Johnson SC, Villarin JJ, et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circulation. 2011;108:837-46.
80. Tang WH, Wu Y, Mann S, et al. Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure. Circulation: Heart failure. 2011;4:59-64.
81. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol. 2011;81:337-44.
82. Tang WH. The ongoing search for a stratified medicine approach in heart failure. J Am Coll Cardiol. 2008;51:2310-2.
83. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6:287-93. (Pubitemid 46505879)